Source: Greiner Bio-One GmbH
Through on-going research and development, our company is constantly launching new and improved sample collection products for clinics, hospitals, laboratories, medical practices and blood transfusion servicesGreiner Bio-One
‘Doctors are the most affected by this risk, the activities with highest risk are primarily venous and capillary blood sampling. Today, many pathogens have been identified that can be transmitted via blood. HBV, HCV and HIV pose the greatest dangers. ‘Studies also show that significantly more infected persons are found among hospital patients than in the “normal population”. Preventive measures, such as the use of a safety product and employee training, can significantly reduce needlestick injuries.’
With the topic of safety is gaining increasing importance in healthcare, Greiner Bio-One reports that it wants to offer customers the safest possible conditions for daily work with patients. ‘For many years Preanalytics has been developing a range of different safety products to reduce the risk of contamination and needlestick injuries,’ the company continues. ‘The first safety products were launched at the turn of the millennium.
‘Vacuette safety blood collection sets are particularly suitable for blood collection from the patients with difficult veins. They are available in different needle sizes and tubing lengths. An integrated safety mechanism that is already activated in the patient’s vein provides even greater safety in the blood collection process. Greiner Bio-One offers reliable protection against potential injury risks with these innovative safety solutions.’
Source: Greiner Bio-One GmbH
Another example, Vacuette CLIX Safety Hypodermic Needle, is equipped with a protective shield for the cannula. Immediately after blood collection, this shield is folded over the cannula and the needle is securely enclosed. A possible needlestick injury can thus be effectively counteracted.
‘Customer feedback is important to the company, which is why it is part of the development of our products. Through on-going research and development, our company is constantly launching new and improved sample collection products for clinics, hospitals, laboratories, medical practices and blood transfusion services. Perfect functionality, maximum safety and high product quality are ensured. For this reason, customers have been placing their trust in Greiner Bio-One for many decades.’
In addition, new products are currently in the research, development and test phase. In 2019 a new and evolutionary safety product will be marketed.
Headquartered in Kremsmünster, Austria, Greiner Bio-One International GmbH focuses on preanalytics, life science, diagnostics and OEM. The extensive product portfolio for routine and special applications in pre- and post-analysis ranges from evacuated blood collection tubes, urine tubes and containers to many other safety and accessory products as well as BSG (erythrocyte sedimentation rate), transport and disposal containers, as well as various auxiliary devices such as decappers. Details: www.gbo.com
Source: Greiner Bio-One International GmbH